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ABSTRACT
Objective Patient and public involvement (PPI)
has become an established theme within the UK
health research policy and is recognised as an
essential force in the drive to improve the quality
of services and research. These developments
have been particularly rapid in the cancer field.
Methods This paper outlines a model of PPI in
research (known as the North Trent Cancer
Research Network Consumer Research Panel,
NTCRN CRP; comprising 38 cancer and palliative
care patients/carers) and the key benefits and
challenges to effective PPI in cancer research.
Results The PPI model has become a sustainable,
inclusive and effective way of implementing PPI
within the cancer context. Challenges include (1)
a lack of time and funding available to support
the PPI model; (2) tensions between different
stakeholder groups when developing and
conducting health research; (3) panel members
finding it difficult to effectively integrate into
research meetings when their role and
contribution is not made clear at the outset or
when unfamiliar language and jargon are used
and not explained; (4) some professionals remain
unclear about the role and practical implications
of PPI in research. However, notwithstanding its
financial and organisational challenges, the way
that the NTCRN CRP is supported has provided a
solid base for it to flourish.
Conclusions PPI provides considerable
opportunities for patients and the public to work
collaboratively with professionals to influence the
cancer research agenda, with the contribution of
PPI to the research process being integral to the
entire process from the outset, rather than
appended to it.
PATIENT AND PUBLIC INVOLVEMENT
IN HEALTH RESEARCH IN THE UK
Over the past 10–15 years, patient and
public involvement (PPI) has become an
established theme within the UK health
research policy1–3 with PPI being recog-
nised as an essential force in the drive to
improve the quality of services and
research. These developments have been
particularly rapid in the cancer field,
where there have been several initiatives
to promote PPI in cancer research.4 5 PPI
in research can be conceptualised as,
“doing research ‘with’ or ‘by’ the public,
rather than ‘to’, ‘about’ or ‘for’ the
public.”2 Three main levels of PPI have
been identified:
1. Consultation (where researchers seek the
views of the public on key aspects of the
research);
2. Collaboration (an ongoing partnership
between researchers and the public
throughout the research process);
3. ‘Publicly-led’ (where the public designs
and undertakes the research and where
researchers are only invited to participate
at the invitation of the public).2
The UK policy commitment to PPI in
research can be seen in a number of
respects: (1) the establishment of
INVOLVE in 1996, to promote PPI in
research in England2; (2) the requirement
that researchers submitting bids to
funders such as the National Institute for
Health Research (NIHR) demonstrate
that the public should be actively
involved in any funded research3 and (3)
the establishment of regional NIHR
Research Design Services that are respon-
sible for bringing clinicians, academics
and members of the public together to
develop research ideas into fully devel-
oped protocols and grant applications.3
Underpinning this policy commitment,
the case for PPI in research rests on three
main arguments4—(1) it is morally and
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ethically correct; (2) it has potential benefits in terms
of improving the quality, relevance and impact of
health research; and (3) it is theoretically and practic-
ally justified.
The North Trent Cancer Research Network model of PPI
There are currently different models and approaches
to PPI in research.4 The model developed within the
North Trent Cancer Research Network (NTCRN),5 6
known as the North Trent Cancer Research Network
Consumer Research Panel—NTCRN CRP, was the
first of its kind to be established at the local level
within the UK. This panel was instituted 12 years ago
in order to: encourage cancer and palliative patients
and carers to engage with health professionals and
academics; and to provide the opportunity for
patients to influence the research agenda and to con-
tribute to the research process from the outset—from
the generation of research questions, through protocol
development and offering advice on issues such as
ethics and patient recruitment, through full
involvement as coresearchers, copresenters at confer-
ences and coauthors of peer-reviewed papers.5
A feature of the NTCRN CRP’s success has been its
support from the outset by academia. It was originally
developed by the Academic Unit of Supportive Care
in the University of Sheffield’s Medical School. It is
now also supported by the Centre for Health and
Social Care Research in the Faculty of Health and
Wellbeing at Sheffield Hallam University. Thus the
CRP is validated and nurtured, at professorial level,
by both biomedical and health services research
cultures.
Since its inception, the panel has grown and now
undertakes PPI activities in four key domains which
include Public Conferences and Engagement, Portfolio
Management, Study Involvement and Research
Governance (table 1 and http://www.ppihr.org.uk/).
This model has been replicated in other UK cancer
networks and is currently held up as a beacon of good
practice by the National Cancer Research Network
and INVOLVE. Such panels provide an important
Table 1 Examples illustrating panel member current involvement and activities
European Union (EU)
Study Involvement INTEGRATE-EU, re palliative care across the EU
National
Public Conferences and Engagement NCRI conference Liverpool
INVOLVE conference
Portfolio Management James Lind Priority Setting Partnership
NHS Head and Neck Oncology Group (DAHNO)
NHS England Clinical Reference Group for Chemotherapy
Study Involvement National Cancer Survivorship Initiative (NCSI)
NIHR Programme Grant ‘Bridging the Age Gap in Breast Cancer’
MRC QUARTZ Trial (Quality of Life and Whole Brain Radiotherapy-for Multiple Brain Metastases)
ENT-UK and Head and Neck 5000 working with the James Lind Alliance
SMP2 National Matrix Study Review Panel
And others
Research Governance Stratified Medicines Governance Board
MRC Review Body for use of Human Biological Material
HRA consultation process on research governance
HRA consultation on use of NHS data
Breast Cancer Campaign Tissue Bank
Regional
Public Conferences and Engagement BME Network and Transformational Survivorship Project Focus Group
Portfolio Management North Trent Network Site Specific Group (BC NSSG)
North Trent Network Site Specific Group (Head and Neck NSSG)
Study Involvement Studies both local, regional and national funded by the NIHR, Charities and local funding bodies
Research Governance Trent Cancer Registry management group
North Trent Cancer Network Patient Partnership Group
South Yorkshire Patient and Public Strategic Planning Group. CLRN, CLAHRC and RDS Collaborative
YCR/CRUK Sheffield Cancer Research Centre Steering Group
Local
Public Conferences and Engagement Sheffield University School of Law—consultation about use of data
Portfolio Management North Trent Cancer Research Network Clinical Trials Executive
Study Involvement SarCaBon—Saracatanib as a novel analgesic for cancer-induced bone pain
FOCCUS—Focus on Cancer Chemotherapy and Unwanted SideEffects (London)
And others
Research Governance Sheffield Experimental Cancer Medicine Centre (ECMC) Executive Committee
Sheffield Cancer Biobank
Sheffield Ethics Committee
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opportunity for the public to get actively involved in
the design and delivery of health research projects by
way of being ‘experts by experience’.6
Benefits and challenges of PPI
A key challenge for those engaged in PPI is to demon-
strate the value-added nature of its impact on research
processes and outcomes. It is difficult to assess object-
ively the impact of PPI on the nature, quality, rele-
vance and effectiveness of health research.7–9 Findings
from a recent systematic review of PPI7 reported that
although the evidence comprised mainly of qualitative
or case study reflections and cross-sectional studies
reporting individual or organisational views of PPI but
with relatively little critical evaluation. Nevertheless,
positive PPI impacts on research were apparent such
as the importance of PPI in identification and priori-
tisation of research, developing patient-focused
research questions, commenting on research proto-
cols, developing research instruments, adapting and
improving the sensitivity of research language in
patient information sheets and invitation letters, and
identifying poor logic and poorly worded questions in
draft questionnaires.7 Additionally, the review found
that PPI helped to foster important links with the
community, which in turn helped researchers to access
participants and improve response rates (including
recruitment rates from seldom heard groups).7
Challenges faced by the NTCRN CRP model of PPI
Challenges specific to the NTCRN CRP can be sum-
marised as follows:
1. A lack of time and funding available to both the aca-
demics facilitating the panel (KC/SHA) and panel
members themselves. In recent years the panel has had
to make annual pleas to different sources to support pan-
ellist work. The panel has relied primarily on the altru-
ism of patients to undertake numerous panel-related
activities on a voluntary basis. One would argue that this
particular panel has been fortunate as several similar
panels have folded due to the lack of financial support.
However, the authors argue that if PPI is central to our
current UK government health research agenda, funding
should be made available to enable many other success-
ful initiatives nationally following the model outlined, so
that patient involvement can be sustained, valued and
recognised;
2. Although there has been a gradual recognition of the
value of PPI within cancer research, tensions still remain
between different stakeholder groups when developing
and conducting health research; furthermore, researchers
have reported concerns about the level of understanding
of the public of certain health research methods (in par-
ticular the rationale for including PPI in biomedical,
especially preclinical, research;
3. Members of the panel find it difficult to effectively inte-
grate into research meetings when their role and contri-
bution is not made clear at the outset or when
unfamiliar language and jargon are used and not
explained;
4. Some professionals are still unclear about the practical
implications of involving the public in research; and
researchers may voice concerns that those members of
the public who get involved in research may not neces-
sarily be representative of potential research participants.
However, lay advocates correspondingly argue that indi-
vidual professionals who take part in research are not
representative of their professions or disciplines.
Additionally, several commentators are critical of
the ability of patients, carers and service users to
provide objective scientific critiques of research,
arguing that they can only provide a non-scientific
subjective view, based on their individual, highly vari-
able experiences, which runs counter to the
medico-scientific paradigm of knowledge develop-
ment.10 Addressing the issue of representativeness,
Boote et al4 argue that although individual patients or
the public cannot be assumed to represent the views
of all members of a particular patient group, their
incorporation into a research team can provide an
added dimension to the conduct and outcome of a
research project which would otherwise be lacking
and possibly ineffective. The challenges to PPI raised
in this paper can be addressed by professionals and
academic researchers providing the following to
patients and service users: an outline of what contri-
bution to the study that the PPI member can make; a
lay summary of the planned research project at the
start of their involvement; a glossary of key terms;
ongoing guidance and support; and an environment
of mutual respect.4
SUMMARY
In conclusion, PPI in research is now an established
theme within the UK health research policy, with a
number of different models and approaches to PPI
emergent. Despite its challenges, PPI provides consid-
erable opportunities for cancer and palliative care
patients, carers and the public to work collaboratively
with professionals and researchers to influence the
research agenda, with the contribution of PPI to the
research process being integral to the entire process
from the outset, rather than appended to it. It is also
important that professionals and researchers who are
considering PPI in their research should seek guidance
from professionals and organisations who have sub-
stantial expertise in this field (eg, INVOLVE, the
NIHR Research Design Services) to ensure good prac-
tice and to optimise mutual benefit from all PPI activ-
ity. Finally we commend the NTCRN CRP model as a
sustainable, inclusive and satisfying way of implement-
ing PPI, at least in a cancer context. Notwithstanding
its financial and organisational challenges, the way
that the NTCRN CRP has continuing academic
support in the city’s two universities has provided a
solid base for it to flourish.
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